Strides Arcolab is down 10%. On the news that it has settled the Mylan outstanding (expected to be $250 million) for a final settlement of $150 million. Mylan bought the Agila division of Strides last year and had kept $250m pending as against potential issues with FDA on a plant that was issued a warning. It seems that has been reduced to $150 million. This is lower but we think it's . . .